ASX:NOX

Noxopharm Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.23 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive NOX News and Ratings via Email

Sign-up to receive the latest news and ratings for Noxopharm and its competitors with MarketBeat's FREE daily newsletter.


About Noxopharm

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.83 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Noxopharm (ASX:NOX) Frequently Asked Questions

What stocks does MarketBeat like better than Noxopharm?

Wall Street analysts have given Noxopharm a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Noxopharm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Noxopharm's earnings last quarter?

Noxopharm Limited (ASX:NOX) released its quarterly earnings data on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter.
View Noxopharm's earnings history
.

Who are Noxopharm's key executives?

Noxopharm's management team includes the following people:
  • Dr. Graham Edmund Kelly, Founder, CEO, MD & Director (Age 76, Pay $371.85k)
  • Mr. David James Franks B.Ec, BEc, CA, F Fin, JP., Company Sec. (Age 51)
  • Mr. Shawn Van Boheemen, Chief Financial Officer
  • Ms. Jeanette Bell, Chief Operating Officer
  • Dr. John Wilkinson, Chief Scientific Officer
  • Dr. Gisela Mautner, Chief Medical Officer

Who are some of Noxopharm's key competitors?

What other stocks do shareholders of Noxopharm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Venture Minerals (VMS), Lincoln Educational Services (LINC) and Immuron (IMRN).

What is Noxopharm's stock symbol?

Noxopharm trades on the ASX under the ticker symbol "NOX."

How much money does Noxopharm make?

Noxopharm has a market capitalization of $0.00 and generates $5.93 million in revenue each year.

What is Noxopharm's official website?

The official website for Noxopharm is www.noxopharm.com.

How can I contact Noxopharm?

The company can be reached via phone at 61 2 9144 2223.


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.